Claim: Medicare 5-year cancer bill tops $21.1 bln: study.
Verdict: SUPPORTS

Retrieved passages:
title: Young Survival Coalition
text: with survivors, caregivers and the medical, research, advocacy and legislative communities to increase the quality and quantity of life for women diagnosed with breast cancer ages 40 and under." This includes lobbying, speaking engagements, conferences and an annual awareness campaign which educates members of the medical community about breast cancer's prevalence in younger women. In the 2013-2014 fiscal year, ending June 30, 2014, Young Survival Coalition reported approximately US$4.78 million in earnings. Of this, US$4.69 million came from contributions and grants, with $.95 million coming from other revenue. That same fiscal year, YSC reported approximately US$4.56 million in expenses. Of

title: American Cancer Society Cancer Action Network
text: health care costs over 25 years. In the Fiscal Year 2012, states will collect $25.6 billion in revenue in tobacco taxes and legal settlements from the 1998 settlement. However, only $45.6 million, or 1.8 percent of that collection will be spent on programs to prevent or stop tobacco use. The CDC recommends $3.7 billion for tobacco cessation and prevention programs, meaning that the allotted $45.6 million is only 12 percent of the recommendation. Of the 50 states, 33 states and the District of Columbia are spending less than a quarter of the recommended amount. Connecticut, Nevada, New Hampshire, Ohio, and

title: Blinatumomab
text: acute lymphoblastic leukemia under the FDA's accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval. When blinatumomab was approved, Amgen announced that the price for the drug would be $178,000 per year, which made it the most expensive cancer drug on the market. Merck's pembrolizumab was priced at $150,000 per year when it launched (in Sept 2014). At the time of initial approval, only about 1,000 patient in the US had an indication for blinatumomab. Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering

title: Carolyn Maloney
text: would be expanded to cover care for a variety of cancers of the lung, trachea, stomach, colon, rectum, liver, bladder, kidney, thyroid and breast. In 2015 when roughly 33,000 responders and survivors were battling an assortment of ailments, Maloney led the effort to extend the bill permanently. After a prolonged and very public push, a total of $8.5 billion in funding was included in the Omnibus Spending bill that was passed in Dec. of 2015 and extended the life of the monitoring and health insurance coverage for 75 years. In the 111th Congress, Maloney introduced "The Breastfeeding Promotion Act" to

title: Healthcare reform debate in the United States
text: costs yet no statistical difference in outcome. Such scenarios offer the opportunity to maintain or improve the quality of care, while significantly reducing costs, through comparative effectiveness research. Writing in the "New York Times", David Leonhardt described how the cost of treating the most common form of early-stage, slow-growing prostate cancer ranges from an average of $2,400 (watchful waiting to see if the condition deteriorates) to as high as $100,000 (radiation beam therapy): According to economist Peter A. Diamond and research cited by the Congressional Budget Office (CBO), the cost of healthcare per person in the U.S. also varies significantly

title: Bevacizumab
text: of £24,000 to £93,000 per quality-adjusted life year (QALY). The addition of bevacizumab to standard treatment can prolong the lives of breast and lung cancer patients by several months, at a cost of $100,000 a year in the United States. For colorectal cancer, Robert J. Mayer wrote in the New England Journal of Medicine that bevacizumab extended life by 4.7 months (20.3 months vs. 15.6 months) in the initial study, at a cost of $42,800 to $55,000. Costs in other countries vary; in Canada it is reported to cost $40,000 CAD per year. In September 2018 claims from Bayer and

title: National Breast Cancer Awareness Month
text: to scrap the program were compared. The total costs to the company of running the early detection program were estimated to be $400,000. Total costs to the company if they chose not to run the program were estimated to be around $1.5 million. Pezzullo (2003) "(Astra)Zeneca’s initial justification for NBCAM was one of basic accounting, not a critique of how women’s healthcare has been assessed or implemented nor a desire to prevent women from developing breast cancer; instead, it was cost-effective for a company to detect cancer in its employees during the disease’s earlier stages." Critics have said that "the

title: National Breast Cancer Coalition
text: Early Detection Program. The Act provides federal funding to help cover more than half of the cost to States that opt to cover treatment for these women through Medicaid. Since this legislation was enacted, all 50 States and the District of Columbia have opted into this program. This is a testament to the continued hard work of NBCC grassroots advocates at the State level. In December 2003, the Medicare Modernization Act was signed into law creating a prescription drug benefit for all Medicare beneficiaries effective in 2006. A provision providing transitional coverage for certain cancer drugs, from September 2004 until

title: Medicare Part D
text: on average, than Part D. Estimating how much money could be saved if Medicare had been allowed to negotiate drug prices, economist Dean Baker gives a "most conservative high-cost scenario" of $332 billion between 2006 and 2013 (approximately $50 billion a year). Economist Joseph Stiglitz in his book entitled "The Price of Inequality" estimated a "middle-cost scenario" of $563 billion in savings "for the same budget window". Former Congressman Billy Tauzin, R–La., who steered the bill through the House, retired soon after and took a $2 million a year job as president of Pharmaceutical Research and Manufacturers of America (PhRMA),

title: Anna Westin Act
text: versus $188 research dollars for Autism and $682 research dollars for Breast Cancer. On May 21, 2015, Congressman Ted Deutch (D-FL-21) and Congresswoman Ileana Ros-Lehtinen (R-FL-27) introduced the bill in the House of Representatives. On July 27, 2015, Senator Amy Klobuchar (D-MN) and Senator Kelly Ayotte (R-NH) introduced the bill in the Senate with support and leadership from Senators Tammy Baldwin (D-WI) and Shelley Moore Capito (R-WV). The Anna Westin Act of 2015 is written to help those affected by eating disorders get the care they need by focusing on improved training and clarity of mental health parity. The bill

title: Medicare Prescription Drug, Improvement, and Modernization Act
text: that the cost would actually be over $500 billion. One month after passage, the administration estimated that the net cost of the program over the period between 2006 (the first year the program started paying benefits) and 2015 would be $534 billion. As of February 2009, the projected net cost of the program over the 2006 to 2015 period was $549.2 billion. Since the enactment of Medicare Prescription Drug, Improvement, and Modernization Act in 2003, only insurance companies administering Medicare prescription drug program, not Medicare, have the legal right to negotiate drug prices directly from drug manufacturers. The Medicare Prescription

title: Breast cancer screening
text: of women with Medicaid insurance, 38% of currently uninsured women, and 33% of women uninsured for more than 12 months). All U.S. states except Utah require private health insurance plans and Medicaid to pay for breast cancer screening. As of 1998, Medicare (available to those aged 65 or older or who have been on Social Security Disability Insurance for over 2 years) pays for annual screening mammography in women aged 40 or older. Three out of twelve (3/12) breast cancer screening programs in Canada offer clinical breast examinations. All twelve offer screening mammography every two years for women aged 50–69,

title: National Breast Cancer Coalition
text: the full benefit was available in 2006, was also included in the law. The transitional benefit was based on the Access to Cancer Therapies Act, a longtime NBCC priority that would provide Medicare coverage for all oral cancer medications. Early warning signs from the regulators writing the rules for implementing the transitional program indicated that breast cancer drugs might not be covered. The inclusion of five breast cancer drugs during the transitional benefit was a struggle that was won with the hard work of NBCC's grassroots advocates. This program will cover 50,000 beneficiaries nationwide with total funding of $500 million.

title: United States National Health Care Act
text: U.S. per-person administrative cost at $1,059. On 13 September 2017, in the aftermath of his 2016 presidential campaign in which single-payer healthcare was among the core tenets of his platform, Sen. Bernie Sanders introduced the "Medicare-for-all Act of 2017" (S. 1804), a parallel bill to the "United States National Health Care Act" (H.R. 676) that was introduced by Rep. John Conyers in the House. Notably, Sanders had introduced a similar version of the bill in 2013, but no other Senators co-sponsored it. This time, his 2017 version attracted sixteen Democratic co-sponsors besides himself: Sanders explains the rationale for the bill

title: Blinatumomab
text: Cancer Center, has calculated that according to "value-based pricing," assuming that the value of a year of life is $121,000 with a 15% "toxicity discount," the market price of blinaumomab should be $12,612 a month, compared to the market price of $64,260 a month. A representative of Amgen said, “The price of Blincyto reflects the significant clinical, economic and humanistic value of the product to patients and the health-care system. The price also reflects the complexity of developing, manufacturing and reliably supplying innovative biologic medicines.” Blinatumomab Blinatumomab (trade name Blincyto) is a biopharmaceutical drug used as a second-line treatment for

title: Healthcare rationing in the United States
text: no statistical difference in outcome. Such scenarios offer the opportunity to maintain or improve the quality of care while significantly reducing costs through comparative effectiveness research. Writing in the "New York Times", David Leonhardt described how the cost of treating the most common form of early-stage, slow-growing prostate cancer ranges from an average of $2,400 (watchful waiting to see if the condition deteriorates) to as high as $100,000 (radiation beam therapy): According to economist Peter A. Diamond and research cited by the Congressional Budget Office (CBO), the cost of healthcare per person in the US also varies significantly by geography

title: Medicare Part D coverage gap
text: coverage maximum of $3,750. Once the total annual drug costs exceed $3750, patients reach the coverage gap, also known as the "doughnut hole". During the coverage gap stage, beneficiaries pay a larger percentage out of pocket until their total out-of-pocket spending reaches $5000. At $5000 of out of pocket spending, beneficiaries reach catastrophic coverage, where they pay either 5% of total drug cost or $3.35 for generics and $8.35 for brand-name drugs. The Low-Income Subsidy (LIS), also known as "Extra Help" provides additional cost-sharing and premium assistance for eligible low-income Medicare Part D beneficiaries with incomes below 150% the Federal

title: American Cancer Society Cancer Action Network
text: has served over 3.9 million women, the program serves less than one in five eligible women at the current funding levels. Some states have been forced to reject people who would be eligible for free mammograms and Pap smears due to state budget cuts. In 2009, 14 states cut budgets for free cancer screenings: Colorado, Minnesota, Connecticut, South Carolina, Utah, Missouri, Washington, Ohio, Massachusetts, Arkansas, Montana, Illinois, Pennsylvania, and Alabama. In 2006, Senators Barbara Mikulski and Kay Bailey Hutchison introduced a bill, supported by ACS CAN, to allow for greater program flexibility and a funding increase of $45 million allowing

title: Disease registry
text: a registry with preventive measures like children vaccination or colonoscopy screening can actually be a cost-saving measure. "A mammogram every 2 years for women aged 50–69 costs only about $9,000 per year of life saved. This cost compares favorably with other widely used clinical preventive services." Registries can be associated with pay-for-performance (P4P) quality based contracts for individual doctors, groups of doctors or even all doctors in a country. For example, the United Kingdom, rewards physicians according to 146 quality measures related with 10 chronic diseases that are tracked electronically. In the United States, Medicare also started a 1.5% P4P

title: National Breast Cancer Coalition
text: in effective advocacy strategies. These efforts focus on legislative priorities set annually and have included: increasing funding for breast cancer research; providing access to health care and clinical trials; and expanding the influence of breast cancer advocates in all aspects of the breast cancer decision-making process. In 1992, NBCC brought about the development of an unprecedented multimillion-dollar breast cancer research project within the Department of Defense that has attracted more than 42,118 research proposals. Federal funding for this program, since its inception in 1991, has reached over $2.5 billion. The National Breast Cancer Coalition has made access to health care